• We completed Jun-2023 Capital Increase and raised approximately RMB1,100 million.
• We received regulatory approval from NMPA for XTR005 (欧韦宁®)
• Glotope commenced radiopharmaceutical CRO/CDMO business
• We obtained clinical trial approval for XTR006